

XPhyto Therapeutics Corp.

14:16 03 Feb 2020

XPhyto Therapeutics brings in C\$2M from placing for European imports business

XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) has raised C\$2 million gross from a fully subscribed private placing to fund its European imports business.

In a statement on Monday, the group said it plans to expand its EU lab processing and storage capacity. The funds will also be used for regulatory compliance, inventory purchase and product development, manufacturing, and distribution, as well as for working capital.

As reported last week, the company struck a three-year supply and distribution deal with Colombian cultivator PharmaCielo Ltd, to serve XPhyto's German medical cannabis business.

READ: XPhyto Therapeutics strikes three-year cannabis supply deal with PharmaCielo for its German business

The Colombian group became its preferred supplier for its European import and distribution business and to supply premium oils and isolates for its medical cannabis products.

XPhyto sold 2,000 convertible debenture units for C\$2 million gross. Each debenture unit consists of C\$1,000 principal amount of 8% unsecured convertible debentures and 1,000 share purchase warrants.

The debentures bear interest at 8% a year, calculated and payable semi-annually and mature two years following the date of issue.

They are also convertible - at the option of the holder - into XPhyto shares at any time prior to the maturity date at a conversion price C\$1 each.

Each warrant is exercisable to acquire one company share at an exercise price of C\$1.50 per warrant share until January 31, 2022, the firm added.

XPhyto also noted today that it has issued 500,000 warrants to PharmaCielo Ltd for the above-mentioned strategic partnership and supply agreement.

Each consideration warrant is exercisable to acquire one share at an exercise price of C\$2 for two years following the date of issuance.

Shares ticked up over 10% in Toronto to C\$1.75 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Price: 3.3

Market Cap: \$179.04 m

1 Year Share Price Graph



August 2019 February 2020 August 2020

Share Information

Code: XPHY

Listing: CSE

52 week High Low
3.55 0.73

Sector: Cannabis

Website: www.xphyto.com

Company Synopsis:

XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM).

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).